 |
|
|
| |
Switching from an Abacavir (ABC)/Lamivudine (3TC)-Based Regimen to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir
Alafenamide (E/C/F/TAF):
Cardiovascular Disease Risk Profile Analysis from a Randomized Controlled Study in Virologically-Suppressed Adults
|
| |
| |
Jules: look at clinical variables input for each of the 3 models and look at results for each model based on variables. Plus bear in mind baseline regimens: 25% on ABC were on integrate, 50% NNRTI, 25% PI.
Reported by Jules Levin
22nd International AIDS Conference
July 23-27 2018
Amsterdam, the Netherlands
Poster #TUPEB098
F Raffi1, A Antinori2, M Ramgopal3, JM Molina4, HJ Stellbrink5, G Rizzardini6, J Olalla7, A Gori8, C Miralles9, P Kumar10, M Das11, ET Chan11, Y Shao11, D Piontkowsky11, SK Chuck11, R Haubrich11
1CHU de Nantes; 2Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS; 3Midway Immunology and Research Center; 4Hôpital Saint Louis; 5ICH Study Center; 6ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco; 7Hospital Costa del Sol; 8ASST di Monza - Azienda Ospedaliera San Gerardo; 9CHU de Vigo - Hospital Alvaro Cunqueiro; 10Georgetown University Medical Center;
11Gilead Sciences, Inc
References
1. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012;13(8):453-468.
2. The D:A:D Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
3. Sabin CA, Reiss P, Ryom L, Phillips AN, Weber R, Law M, Fontas E, Mocroft A, de Wit S, Smith C, Dabis F, d'Arminio Monforte A, El-Sadr W, Lundgren, J. D. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. BMC Medicine 2016;14:61.
4. Ryom R, Lundgren JD, El-Sadr W, Reiss P, Phillips A, Kirk O, Weber R, Fontas E, Monforte AD, de Wit S, Dabis F, Hatleberg CI, Sabin C, Mocroft A. On behalf of the D:A:D Study group. Association between Cardiovascular Disease and Comptemporarily Used Protease Inhibitors. [Presentation]. CROI, 13-16, February 2017, Seattle, WA.
5. D:A:D Study Group, Smith C. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS. 2010;24(10):1537-1548.
6. Elion RA, Althoff KN, Zhang, J, Moore, RD, Gange S, et al. Recent abacavir use increases risk for Types 1 and 2 myocardial infarctions among adults with HIV. JAIDS 2018.
7. Gori A, Rizzardini G, Miralles C, Olalla J, Molina JM, Raffi F, Kumar P, Antinori A, Ramgopal M, Stellbrink HJ , Das M, Chu H, Ram R, Garner W, Chuck SK, Piontkowsky D, Haubrich R. Switching from An Abacavir (ABC)/Lamivudine (3TC)-Based Regimen to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) is Efficacious and Safe: Week 24 Primary Analysis of a Randomized Controlled Study in Virologically-Suppressed Adults [Presentation]. XVIII Congrès National de la SFLS, 19-20 October 2017, Nice Acropolis, France.
8. European AIDS Clinical Society (EACS) Guidelines Version 9.0. October 2017. http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html. Accessed 6 June 2018.
9. US Preventive Services Task Force. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults US Preventive Services Task Force Recommendation Statement. JAMA. 2016;316(19):1997-2007. doi:10.1001/jama.2016.15450
10. Friis-Møller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, De Wit S, Monforte AD, Kirk O, Fontas E, Sabin C, Phillips A, Lundgren J, Law M; D:A:D study group. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Prev Cardiol. 2016 Jan;23(2):214-23.
11. Goff DC, Lloyd-Jones D, Bennet G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(Suppl 2):S49-S73
12. Agostino 2008 D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel, W. B. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117(6), 743-753.
13. Feinstein MJ, Nance RM, Drozd DR, et al. Assessing and Refining Myocardial Infarction Risk Estimation amoeduce Atherosclerotic ng Patients with Human Immunodeficiency Virus: Centers for AIDS Research Network of Integrated Clinical Systems (CNICS). JAMA cardiology. 2017;2(2):155-162. European AIDS Clinical Society (EACS) Guidelines Version 9.0. October 2017. http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html. Accessed 6 June 2018.
|
| |
|
|
|
|
|
